KIR3DL1 and leukemia: Since the initial studies describing the graft versus leukemia benefits of allogeneic NK cells in KIR-mismatched transplantation and the benefit of alloreactive donor T cells, multiple studies have expanded on the adoptive potential of immune-based therapy.